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Dysregulation of TAR DNA-binding protein 43 (TDP-43) is a hallmark feature of frontotemporal 
dementia (FTD) and amyotrophic lateral sclerosis (ALS), two fatal neurodegenerative 
diseases. TDP-43 is a ubiquitously expressed RNA-binding protein with many physiological 
functions, playing a role in multiple aspects of RNA metabolism. We developed transgenic 
mice conditionally overexpressing human wild-type TDP-43 protein (hTDP-43-WT) in 
forebrain neurons, a model that recapitulates several key features of FTD. After post-
weaning transgene (TG) induction during 1 month, these mice display an early behavioral 
phenotype, including impaired cognitive and social function with no substantial motor 
abnormalities. In order to expand the analysis of this model, we took advantage of the 
temporal and regional control of TG expression possible in these mice. We behaviorally 
evaluated mice at two different times: after 2 weeks of post-weaning TG induction (0.5 month 
group) and after subsequent TG suppression for 2 weeks following that time point [1 month 
(sup) group]. We found no cognitive abnormalities after 0.5 month of hTDP-43 expression, 
evaluated with a spatial working memory task (Y-maze test). Suppression of TG expression 
with doxycycline (Dox) at this time point prevented the development of cognitive deficits 
previously observed at 1 month post-induction, as revealed by the performance of the 
1 month (sup) group. On the other hand, sociability deficits (assessed through the social 
interaction test) appeared very rapidly after Dox removal (0.5 month) and TG suppression 
was not sufficient to reverse this phenotype, indicating differential vulnerability to hTDP-43 
expression and suppression. Animals evaluated at the early time point (0.5 month) post-
induction do not display a motor phenotype, in agreement with the results obtained after 
1 month of TG expression. Moreover, all motor tests (open field, accelerated rotarod, limb 
clasping, hanging wire grip) showed identical responses in both control and bigenic animals 
in the suppressed group, demonstrating that this protocol and treatment do not cause 
non-specific effects in motor behavior, which could potentially mask the phenotypes in 
other domains. Our results show that TDP-43-WT mice have a phenotype that qualifies 
them as a useful model of FTD and provide valuable information for susceptibility windows 
in therapeutic strategies for TDP-43 proteinopathies.
Keywords: TDP-43, frontotemporal dementia, amyotrophic lateral sclerosis, transgenic mice, behavior, 
animal model, proteinopathy
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INTRODUCTION
Neurodegenerative diseases are incurable and debilitating 
conditions that arise as a consequence of the progressive 
degeneration and/or death of nerve cells. This heterogeneous 
group of disorders is characterized by behavioral changes that 
differ according to the disease entity. Among these, most forms 
of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia 
(FTD) show clinic-pathological overlap. These diseases may 
represent a single pathological entity with diverse clinical 
manifestations (Geser et  al., 2010; Burrell et  al., 2016), included 
within the heterogeneous group of “TDP-43 proteinopathies.” 
TDP-43 pathology frequently associates with other disorders, 
including Alzheimer’s disease, dementia with Lewy body, 
hippocampal sclerosis, and chronic traumatic encephalopathy, 
among others (Kovacs, 2016). The umbrella term “TDP-43 
proteinopathies” was coined shortly after the discovery that most 
forms of ALS and around 45% of FTD cases have TDP-43-positive 
neuronal and glial inclusions as a major pathological hallmark 
(Arai et  al., 2006; Neumann et  al., 2006; Cairns et  al., 2007). 
Roughly, another 45% of FTD cases is characterized with tau 
pathology and 5–10% with FUS accumulation, while a small 
percentage of ALS cases is associated with abnormalities in 
SOD1, FUS, or other proteins (Nguyen et  al., 2018).
TDP-43 is a highly conserved and widely expressed 
RNA-binding protein (RBP) that normally resides predominantly 
in the nucleus of all cells. It has been described to be  involved 
in different cellular processes, most conspicuously RNA 
metabolism, including RNA translation, splicing, and transport 
(Ratti and Buratti, 2016). Dysregulation of RNA metabolism 
can occur at multiple levels of RNA processing including 
transcription, splicing, mRNA transport, stability, and translation 
(Coyne et  al., 2017). This, in turn, will have numerous 
implications for the generation of biochemical, pathological, 
and behavioral phenotypes. Although several animal models 
of FTD/ALS disease have been developed in the past few 
years, an important caveat is that none exactly mimic the 
pathophysiology and the phenotype of human FTD/ALS 
(Alrafiah, 2018). However, studying the behavioral impact of 
modulating FTD/ALS-related RBPs shows that they recapitulate 
different clinical presentations in patients, representing an array 
of behavioral domains that include motor, cognitive, and social 
symptoms (Philips and Rothstein, 2015; Nolan et  al., 2016; 
Ahmed et  al., 2017; Tan et  al., 2017; Ittner et  al., 2018).
Given that multiple (although not all) forms of both sporadic 
and familial FTD/ALS cases of different genetic origin 
(i.e., mutations in C9orf72, progranulin, TARDBP, etc.) converge 
in a common pathological presentation that involves TDP-43 
dysregulation (Seelaar et  al., 2011; Renton et  al., 2014), there 
is a growing need in the field for understanding the pathological 
and behavioral consequences of these abnormalities.
Using a mouse model of TDP-43 proteinopathies that 
conditionally overexpresses the wild-type human TDP-43 protein 
(hTDP-43-WT) in forebrain neurons and reproduces 
neuropathological changes of the FTD/ALS spectrum (Igaz 
et  al., 2011), we  have recently shown that they display early 
behavioral phenotypes in the cognitive and social domains 
(Alfieri et  al., 2016). Interestingly, these animals also exhibit 
progressive motor abnormalities after prolonged transgene 
expression (Alfieri et al., 2016). These behavioral features provide 
an interesting correlate to human disease, starting with a more 
“pure” FTD-like phenotype and later evolving into a FTD with 
motor neuron disease presentation (expressing some ALS-like 
features). A major advantage of using inducible transgenic 
systems is the possibility to prevent or reverse specific phenotypes 
after transgene suppression. This, in turn, may provide 
information on the differential susceptibility of the diverse 
phenotypical manifestations of TDP-43 manipulation, with 
implications for understanding pathological onset and progression 
in human disease and defining time windows with 
therapeutic relevance.
In this work, we  aimed to investigate how short-term 
transgene suppression affects the early behavioral phenotypes 
displayed by conditional TDP-43-WT mice (Alfieri et al., 2016). 
In particular, we studied (1) if the cognitive and social phenotypes 
previously described were present after a shorter period 
(0.5  month) of transgene expression, and (2) the effect of the 
suppression on both affected domains and in motor behaviors, 
which were preserved after 1  month of transgene expression. 
Assessment of the different behavioral domains both before 
and after transgene suppression indicates that sociability is 
rapidly impaired while cognitive and motor performance is 
preserved after 0.5  month of hTDP-43 expression. Moreover, 
suppression of transgene expression prevented the development 
of cognitive deficits and had no effect on motor behavior. 
Remarkably, social behavior remained compromised after 
transgene suppression, indicating differential vulnerability to 
TDP-43 manipulation in the neuronal circuits underlying 
diverse behaviors.
These results emphasize the need to comprehensively evaluate 
the behavioral phenotypes in multiple disease models and 
suggest that the timing of treatment could widely influence 




This study was carried out in accordance with the 
recommendations of the National Animal Care and Use 
Committee of the University of Buenos Aires (CICUAL). The 
protocol was approved by the CICUAL. Mice were kept under 
a 12-h light/dark cycle, with controlled temperature (23 ± 2°C) 
and humidity (40–60%) and had ad libitum access to food 
and water. To produce hTDP-43 transgenic lines, as described 
previously (Igaz et al., 2011), pronucleus of fertilized eggs from 
C57BL/6J  ×  C3HeJ F1 matings were injected with a vector 
containing hTDP-43-WT cDNA. Monogenic tetO-TDP-WT12 
mice were bred to Camk2a-tTA mice (Mayford et  al., 1996; 
Jackson Laboratory) generating non-transgenic, tTA monogenic, 
single tetO-TDP-43 transgenic mice (non-TDP-43 expressing 
control mice) and bigenic mice expressing hTDP-43-WT12 
(hereinafter referred to as tTA/WT12).
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Mice were treated with 0.2 mg/ml Dox (Doxycycline Hyclate, 
sc-204734A, Santa Cruz Biotechnology) in drinking water to 
avoid prenatal and postnatal developmental effects of transgene 
expression. hTDP-43 expression was induced by switching mice 
to regular drinking water (without Dox) at weaning (postnatal 
day 28). Mice were analyzed at different time points (Figure 1A).
Mice were screened for the presence of the transgene using 
genomic DNA isolated from ear biopsies. PCR amplification 
was done with the following primers: TDP-forward 
(TTGGTAATAGCAGAGGGGGTGGAG), MoPrP-reverse 
(TCCCCCAGCCTAGACCACGAGAAT), Camk2a-tTA-forward 
(CGCTGTGGGGCATTTTACTTTAG), and Camk2a-tTA-reverse 
(CATGTCCAGATCGAAATCGTC) as previously described 
(Igaz et  al., 2011; Alfieri et  al., 2014). To homogenize genetic 
background and minimize variability, the TDP-43-WT12 
transgenic line used in these experiments was established by 
crossbreeding with C57BL/6J mice for >10 generations. For 
both non-transgenic and transgene-expressing groups, animals 
of either sex were included in all experimental groups.
Transgene Suppression Protocol
For suppression experiments, mice were treated again with 
0.2  mg/ml Dox in drinking water at 0.5  month after weaning 
to suppress transgene expression for 2 weeks, as indicated in 
Figure 1A. Animals were analyzed before the transgene 




FIGURE 1 | TDP-43 expression pattern in inducible TDP-43-WT transgenic mice. (A) Experimental design: transgene expression was inactive until postnatal day 
28 by treatment with Dox. For the suppression protocol, mice were treated again with Dox at 0.5 month post-weaning to suppress transgene expression for 2 
weeks. The behavioral analysis (motor, cognitive, and social) was performed at 0.5 month post-weaning (0.5 month mice) and at 1 month post-weaning [1 month 
(sup) mice]. The results on these mice were compared with mice in which transgene expression was preserved until 1 month post-weaning (1 month mice).  
(B–E) Expression of human TAR DNA-binding protein 43 (TDP-43) in tTA/WT12 mice. (B) Schematic diagrams (adapted from Paxinos and Franklin, 2008) showing 
different hTDP-43-expressing brain areas (indicated by the labeled boxes) such as somatosensory cortex (SSC), hippocampal cornus ammonis 1 (CA1), and dentate 
gyrus (DG). (C–E) Double immunofluorescence of total TDP-43 (human + mouse TDP-43) and human TDP-43 in representative coronal brain sections of control, 
tTA/WT12 1 month and tTA/WT12 1 month (sup) mice. High power micrographs of boxed areas in B are shown: SSC (C), hippocampal CA1 region (D), and DG (E). 
Scale bar: 50 μm.
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after transgene suppression, at 1 month after weaning [1 month 
(sup) mice]. These mice were also compared with animals in 
which transgene expression was maintained until 1  month 
(1 month mice) after weaning.
Behavioral Studies
All behavioral tasks were performed during the light phase 
(lights on at 7 a.m.; lights off at 7 p.m.) with the exception 
of the Y-maze spontaneous alternation, which was conducted 
during the initial dark phase (7:00 p.m to 9:00 p.m.) to maximize 
exploratory behavior and consistently obtain a high number 
of arm visits. Animals were allowed to habituate in the 
experimental room (with attenuated light and sound) for at 
least 1  h before the tests. All tests were recorded through a 
video camera mounted above the experimental room (unless 
noted) and mouse position was analyzed by automatic video 
tracking software (ANY-maze, Stoelting Co.). All mazes and 
objects used in behavioral analysis were cleaned with 10% ethanol 
between test sessions and sanitized with 70% ethanol at the 
end of the day.
In agreement with what we  previously demonstrated in 
experiments with TDP-43-∆NLS and TDP-43-WT transgenic 
mice (Alfieri et  al., 2014, 2016), all non-bigenic offspring 
(non-transgenic and both single transgenic mice) exhibited 
similar behavioral responses. Thus, for all subsequent behavioral 
tests and other experimental analyses, we  grouped these 
genotypes under the control group to compare against bigenic 
(tTA/WT12) mice.
Y-Maze Spontaneous Alternation Test
The horizontal Y-shaped maze consisted of three identical 
arms of transparent Plexiglas (43  cm × 4  cm × 12.5  cm) 
placed at 120° angles to each other (Belforte et  al., 2010; 
Alfieri et  al., 2014). The test was performed in a room with 
visual clues and controlled illumination (30 lux), as previously 
described (Alfieri et  al., 2014, 2016). Animals were placed at 
the end of one arm facing the center and allowed to freely 
explore the maze for 8  min without training, reward, or 
punishment. All activities were recorded with a computer-
linked video camera mounted above the maze. Mouse position 
was detected by automatic video tracking (ANY-maze, Stoelting). 
An alternation was defined as consecutive entrances into each 
of the three arms without repetition. The percentage of 
spontaneous alternation was calculated as the number of 
alternations divided by the possible alternations [(# alternations)/
(total arm entries − 2) × 100]. Total entries were scored as 
an index of ambulatory activity in the Y maze and mice with 
scores below 12 were excluded from this test. All mice were 
tested between 7:00 p.m. and 9:00 p.m. (dark phase) to maximize 
exploratory behavior (Belforte et  al., 2010).
Social Interaction Test
The test apparatus comprised a black Plexiglas rectangular 
box (40.6 cm × 15 cm × 23 cm) divided into three interconnected 
chambers. The floor of the apparatus was covered with clean 
bedding. The task was performed as previously described 
(Alfieri et  al., 2014, 2016). For the habituation phase, two 
identical cylinders of transparent Plexiglas (7  cm diameter, 
14  cm tall) with multiple small holes (0.5  cm diameter) to 
allow olfactory, visual, and auditory interaction, were placed 
in each one of the end chambers. Then, the test mouse was 
placed in the central chamber for 5 min and allowed to explore 
the entire social interaction apparatus. During the test phase, 
a black object (non-social stimulus) was placed into one 
cylinder on the “non-social” chamber and a stimulus mouse 
(a 21–26  days old C57BL/6J male mouse) was placed into 
the cylinder on the “social” chamber. The test mouse was 
placed again in the central chamber and allowed to freely 
explore the apparatus for 10  min. Sniffing time for the social 
and non-social stimulus was manually scored. Mouse position 
and time spent in each chamber were analyzed by automatic 
video tracking (ANY-maze, Stoelting).
Open Field Test
To analyze general locomotion and exploratory behavior in a 
novel environment, we performed the open field test as previously 
described (Alfieri et  al., 2014, 2016). The open field apparatus 
consisted of a transparent Plexiglas (40  cm × 40  cm × 40  cm) 
arena with a white floor virtually divided into two zones: 
periphery and center (comprising 50% of the total area centered). 
The test mouse was able to explore the novel environment 
for 20  min. Total distance and center distance traveled by 
the animal were analyzed. Time bin analysis (every 5  min) 
was also used. Room illumination was kept at 50 lux. Mouse 
position was determined by automatic video tracking 
(ANY-maze, Stoelting).
Accelerated Rotarod
For the assessment of motor coordination and balance, we used 
a rotarod apparatus (Ugo Basile, model 7600). The test was 
performed as previously described (Alfieri et  al., 2016). Briefly, 
the accelerating rotarod test was set at 4–40  rpm over 300  s, 
and four trials per test were performed, with a 2-min interval 
between trials. The latency to fall off from the rotarod was 
automatically quantified. Mice that rotated passively were removed 
from the apparatus and scored as fallen.
Clasping Phenotype
The presence of clasping was evaluated as previously described 
(Igaz et al., 2011; Alfieri et al., 2014). hTDP-43-WT12 transgenic 
mice and age-matched control mice were suspended by the 
tail 30  cm over an open cage for 30  s. A positive clasping 
posture was noted for mice that clasped their limbs within 
5  s of suspension while maintaining the clasping posture until 
lowered to the cage.
Hanging Wire Grip Test
Grip strength was studied using a standard wire cage and 
performed as previously described (Alfieri et  al., 2014, 2016). 
Briefly, the mouse was placed on the top of the lid, then the 
lid was shaken lightly to cause the mouse to grip the wires 
and next turned upside down. The upside-down lid was held 
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at a height of 20  cm, and the latency to fall off the wire lid 
was registered. A 60-s cutoff time was used.
Brain Tissue Collection
All animals were deeply anesthetized with intraperitoneal 
administration of 5% chloral hydrate (1  ml/30 gr). Next, mice 
were perfused transcardially with ice-cold PBS (0.1 M, pH 7.4) 
supplemented with 10  U/ml heparin. The brains were 
immediately extracted and fixed overnight by immersion in 
4%  paraformaldehyde (PFA), and then cryoprotected in 10 
and 30% sucrose in PBS for immunofluorescence analyses.
Immunofluorescence
Fixed frozen hemispheres were cryosectioned (50  μm) on a 
sliding freezing microtome (SM 2010R; Leica). The brain 
slices were stored at −20°C in cryoprotecting solution (50% 
glycerol, 50% PBS). Double immunofluorescence was performed 
as follows: the coronal free-floating sections were washed 
2 × 5  min with PBS, permeabilized with 1% Triton X-100  in 
PBS for 1  h, and blocked for 1  h with 0.3% Triton X-100 
and 5% goat serum in PBS. The primary antibodies (diluted 
in 0.3% Triton X-100 and 3% goat serum in PBS) were 
incubated overnight at 4°C with the indicated dilutions: 
polyclonal rabbit anti-TDP-43 (as described previously in Igaz 
et  al., 2008) 1:30,000 and monoclonal mouse anti-hTDP-43 
(60019-2; Proteintech) 1:10,000. After washing 2 × 5  min 
with PBS, secondary antibodies conjugated with Alexa Fluor 
488 (Invitrogen) and rhodamine (Jackson Laboratories) diluted 
in 0.3% Triton X-100 and 5% goat serum in PBS were 
incubated for 4 h at room temperature. Nuclear counterstaining 
was performed with Hoechst 33342 (2 μg/ml; Sigma). Sections 
were mounted using 30% glycerol in PBS on gelatin-coated 
slides. The images were obtained by a Zeiss Axio Imager 2 
microscope equipped with APOTOME.2 structured 
illumination, using a Hamamatsu Orca Flash 4.0 camera.
Statistical Analysis
Statistical tests were performed as follows, as described in the 
text and figure legends for each dataset. Student’s t test was 
used when comparing only two groups on one behavioral 
measure. Repeated measures (RM) two-way analysis of variance 
(ANOVA) followed by Newman-Keuls multiple comparison post 
hoc test, when comparing three or more groups in the social 
interaction experiments. RM-ANOVA followed by Bonferroni’s 
multiple comparisons post hoc test was used for accelerated 
rotarod. Fisher exact test was performed for clasping analysis. 
When non-parametric tests were required (hanging wire grip 
test), Mann-Whitney U test was used. Statistical analysis of 
behavioral tests was performed using PRISM 6 (Graph Pad 
software) or Statistica 7 (Stat Soft). Data are presented as mean 
values ± SEM. A p < 0.05 was considered statistically significant.
RESULTS
In a recent work, we  performed a detailed characterization 
of the behavioral changes occurring in hTDP-43-WT mice 
(Alfieri et  al., 2016). Using an induction protocol that avoids 
developmental and early postnatal deficits (Igaz et  al., 2011), 
we  showed that post-weaning expression of hTDP-43  in 
forebrain neurons for 1  month led to social and cognitive 
phenotypes in the absence of clear motor abnormalities. The 
main goals of this work were to understand whether these 
social and cognitive changes occur earlier following 
hTDP-43 expression and to define if the suppression of 
transgene expression might prevent or reverse the 
behavioral deficits.
tTA/WT12 bigenic mice or control littermates were induced 
at weaning (postnatal day 28) by removing Dox from their 
water supply (Figure 1A). Paralleling our studies using mice 
that express a cytoplasmic form of TDP-43 (hTDP-43-∆NLS) 
under the same promoter system (Alfieri et al., 2014), we defined 
a protocol that induces transgene expression for 2  weeks, and 
then, we  suppressed hTDP-43 expression by treating mice for 
two additional weeks with Dox. We  analyzed these animals 
at two time points, thus defining two experimental groups: 
mice after 2 weeks of Dox removal (0.5 month) and mice 
with subsequent transgene suppression due to treatment with 
Dox for additional 2 weeks, termed 1 month (sup) (Figure 1A). 
In this way, we  can study both the installment/phenotype 
development at very early time points and the effect of transgene 
suppression on behavioral performance. This analysis, combined 
with our data from tTA/WT12 mice induced for 1  month 
(Figure 1A; Alfieri et al., 2016), allows us to study and interpret 
the susceptibility of different behavioral domains to 
transgene suppression.
In order to assess proper regulation of transgene expression 
within our experimental timeline, we  performed double 
immunofluorescence studies (Figures 1C–E). We  used a 
polyclonal antibody (referred as total TDP-43) that reacts 
to both endogenous (mouse) and transgenic (human) forms 
of TDP-43, and a monoclonal antibody that only recognizes 
the human isoform of the TDP-43 protein (in this case, 
human TDP-43-WT), termed human TDP-43 (hTDP-43). 
Representative micrographs from forebrain regions (see diagram 
in Figure  1B), including the somatosensory cortex (SSC, 
Figure 1C), hippocampal cornus ammonis 1 (CA1) region 
(Figure 1D), and Dentate Gyrus (DG, Figure 1E), show 
that bigenic tTA/WT12 mice correctly express transgenic 
human TDP-43 in the nucleus after 1 month of Dox removal 
(1 month group). On the contrary, bigenic mice from the 
1 month (sup) group are almost completely devoided of 
hTDP-43 immunoreactivity. As expected, mice from the 
control group only show signal for the total TDP-43 antibody 
but no hTDP-43 staining (Figures 1C–E). Interestingly, total 
TDP-43 staining in the 1  month (sup) animals (but not in 
the control or 1  month groups) showed that a subset of 
cortical and hippocampal cells display altered nuclear 
morphology and/or nuclear TDP-43 distribution, suggesting 
that the mechanisms for coping with hTDP-43 overexpression 
and recovery might differ. These results demonstrate both 
robust nuclear expression of the transgene after Dox removal 
and proper suppression of hTDP-43 expression following 
re-installment of Dox treatment.
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Suppression of TDP-43-WT Expression 
Prevents Installment of Early  
Cognitive Deficits
We have recently demonstrated that post-weaning overexpression 
of hTDP-43-WT during 1 month leads to cognitive deficits 
in our inducible tTA/WT12 mouse model (Alfieri et al., 2016). 
These phenotypes include alterations not only in object 
recognition memory but also in spatial working memory, as 
assessed by the object recognition test and the Y-maze 
spontaneous alternation test, respectively. These cognitive tasks 
rely on cortical (perirhinal, prefrontal) and hippocampal 
functional integrity (Lalonde, 2002; Warburton and Brown, 
2010), and these areas widely express the transgene (Figure  1; 
Igaz et al., 2011). Since typical clinical features of FTD patients 
include alterations of prefrontal-dependent executive functions 
(Seelaar et  al., 2011), we  used the Y-maze task to monitor 
the impact of short-term hTDP-43 overexpression in this type 
of behavior (Figure 2A). The Y-maze test relies on the animal’s 
preference to explore a new arm of the maze rather than 
returning to a previously visited arm (Lalonde, 2002). When 
tTA/WT12 mice were tested after 0.5  month of induction, 
control mice showed spontaneous alternation percentages 
avoiding the previously visited arms and bigenic mice were 
indistinguishable from control mice, indicating normal working 
memory in both groups (t(21) = 0.8096, p = 0.4273; Figure 2B, 
left panel). Importantly, locomotion (estimated by the number 
of arm entries) was similar between groups (t(21)  =  0.2947, 
p  =  0.7711; Figure 2B, right panel). These data, together with 
our results showing that tTA/WT12 mice displayed altered 
performance in the Y-maze test 1 month post-induction (Alfieri 
et  al., 2016), indicate that cognitive deficits (specifically, spatial 
working memory) begin to occur in the 0.5–1  month time 
window of transgene expression in this mouse model.
To evaluate if short-term (2  weeks) transgene suppression 
could prevent the installment of this deficit, we  reintroduced 
Dox in the drinking water of these animals after the 0.5 month 
time point and assessed Y-maze performance 1  month post-
weaning, in a group termed 1 month (sup) (see timeline in 
Figure 1A). Student’s t test analysis established that bigenic 
animals from the 1 month (sup) group did not show significant 
differences compared with control mice (t(20)  =  1.658, 
p  =  0.1128; Figure 2C, left panel). Again, the total number 
of arm entries was similar between groups (t(20)  =  0.3583, 
p  =  0.7238; Figure 2C, right panel). In summary, these data 
demonstrate that short-term suppression of transgene expression 
can prevent cognitive abnormalities in young TDP-43-WT mice.
TDP-43-WT Mice Develop Sociability 
Abnormalities Very Rapidly After hTDP-43 
Induction and They Persist After 
Transgene Suppression
Within the spectrum of clinical presentations of TDP-43 
proteinopathies, deficits in social behavior are a conspicuous 
feature of FTD patients (Desmarais et  al., 2017). Moreover, 
we  and others have shown that altered sociability is a feature 
of different animal models of FTD, including those based on 
manipulations of TDP-43, tau, fused in sarcoma (FUS), 
progranulin, and CHMP2B (Ghoshal et al., 2012; Filiano et al., 
2013; Alfieri et  al., 2014, 2016; Koss et  al., 2016; Vernay et  al., 
2016; Shiihashi et  al., 2017). Specifically, we  demonstrated that 
both inducible transgenic mice expressing either cytoplasmic 
(TDP-43-∆NLS) or nuclear (TDP-43-WT) form of human 
TDP-43 show altered early social phenotypes, 1 month post-
induction (Alfieri et al., 2014, 2016). At this time point, bigenic 
tTA/WT12 mice display decreased performance in the three-
chamber social interaction test (Figure 3A) respective to control 
animals (Alfieri et  al., 2016), although to a lesser degree than 
TDP-43-∆NLS mice (Alfieri et  al., 2014).
To determine whether this phenotype was detectable right 
before starting the suppression protocol, we  studied sociability 
in tTA/WT12 mice 0.5  month after hTDP-43 induction. As 
expected, control mice spent more time interacting with the 
demonstrator mouse (S, social stimulus) than with the inanimate 
object (NS, non-social stimulus). Bigenic mice showed a deficit 
in social interaction evidenced by a significant decrease in time 
spent in direct social exploration of a conspecific demonstrator 
(sniffing time, RM-ANOVA, interaction F(1,24) = 6.32, p = 0.019; 
Figure 3B). This reduced social activity results from a 
A B C
FIGURE 2 | Short-term hTDP-43-WT suppression prevents installment of working/spatial memory deficits. (A–C) Y-maze spontaneous alternation task.  
(A) Scheme of the Y-maze. (B,C) Mice were allowed to explore the maze freely for 8 min without training, reward, or punishment. Alternation behavior (defined as a 
consecutive entrances into each of the three arms without repetition) and total arms entries, as an index of locomotion activity, were quantified. (B) 0.5 month mice 
Y-maze performance (n = 12, 11 for control and bigenic 0.5 month mice, respectively). (C) 1 month (sup) mice performance (n = 12, 10 for control and bigenic  
1 month (sup) mice, respectively).
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significant reduction in the mean sniffing time per contact 
(RM-ANOVA, interaction F(1,24)  =  4.60, p  =  0.042; Figure 3C) 
with no significant differences in the number of social contacts 
among social conditions (RM-ANOVA, S-NS preference 
F(1,24) = 46.98, p < 0.0001; Figure 3D). Decreased social interaction 
cannot be attributed to an altered motor function (non-significant 
differences in the total number of chamber entrances, 
RM-ANOVA, S-NS preference F(1,24) = 0.57, p = 0.46, genotype 
F(1,24)  =  0.54, p  =  0.47, interaction F(1,24)  =  0.51, p  =  0.48, 
Figure 3E, and total traveled distance, 16.95  ±  2.57 vs. 
14.80  ±  1.77  m for control and bigenic mice, respectively; 
t(24)  =  0.7137, p  =  0.4823, Student’s t test) or to general 
A
A
F G H I
B C D E
FIGURE 3 | tTA/WT12 mice display early sociability deficits, which persist after transgene suppression. (A) Scheme of three-chamber social interaction apparatus, 
a rectangular box made of a black Plexiglass divided in three interconnected chambers. Social behavior was analyzed at 0.5 months off Dox (0.5 month mice)  
(B–E), and after 2 weeks of Dox transgene suppression treatment [1 month (sup)] (F–I). (B,F) The time spent sniffing the social (S; P21–P28 male mouse) or the 
non-social (NS; black plastic object) stimulus during a 10 min session (test phase) was recorded. (C,G) Mean sniffing time per contact. (D,H) Number of social 
contacts. (E,I) Total entries in each chamber. *p < 0.05, **p < 0.01, ***p < 0.001, two-way RM-ANOVA/Newman-Keuls post hoc test, except for (G), significance of 
main effects. n = 11, 15 for control and bigenic 0.5 month mice, respectively; n = 10, 13 for control and bigenic 1 month (sup) mice, respectively. n.s., not 
significant. Data represent mean ± SEM.
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FIGURE 4 | Motor domain remains unaltered after 2 weeks of suppression of hTDP-43-WT transgene. (A–D) Open-field task; locomotor and exploratory behaviors 
were preserved in suppressed hTDP-43-WT mice. (A) Occupancy plot. Representative heat maps for time spent by subject mice during the entire session are 
shown. The heat map was constructed based on body position. (B) Total distance traveled. (C) Total distance traveled in time segments of 5 min. (D) Relative 
center distance. No significant differences were found between controls and bigenic animals in locomotion or exploration. (E) Motor coordination and balance were 
not affected after suppression of hTDP-43-WT expression. Accelerated rotarod performance (4–40 rpm/5 min): four trials per test were performed during the test 
day with a 2-min interval between trials. Latency to fall off the apparatus was recorded. (F–G) No signs of spasticity or motor strength deficits are detected in 
suppressed hTDP-43-WT mice. (F) The absence of clasping phenotype in both 0.5 month and 1 month (sup) mice. Percentage of animals positive for abnormal 
clasping and number of animals positive/total tested are shown. (G) Hanging wire grip test. Grip strength was assessed using a standard wire cage turned upside 
down. The latency to fall off the wire lid was quantified; a 60-s cutoff time was used. No significant differences were found between control and bigenic animals 
[p > 0.05 Student’s t test in (B,D), Mann-Whitney U test in (G), repeated-measures ANOVA in (C,E), Fisher’s exact test in (F)]. n = 12, 15 for control and bigenic  
0.5 month mice, respectively; n = 12, 14 for control and bigenic 1 month (sup) mice, respectively. Data represent mean ± SEM.
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deficits in novelty exploration (both groups interact similarly 
with the novel object, compare non-social control vs. non-social 
bigenic groups in Figures 3B–D).
Next, we assessed the effect of turning off hTDP-43 expression 
on social behavior. Notably, transgene suppression in the 
1 month (sup) group did not cause any improvement in social 
interaction in bigenic mice respective to controls (RM-ANOVA, 
interaction F(1,21)  =  6.41, p  =  0.019; Figure 3F). Moreover, the 
social phenotype showed a tendency to worsen after transgene 
suppression, since both the mean contact duration (RM-ANOVA, 
S-NS preference F(1,21) = 27.76, p < 0.0001; genotype F(1,21) = 5.60, 
p  =  0.027; Figure 3G) and the total contact number 
(RM-ANOVA, interaction F(1,21)  =  4.75, p  =  0.041; Figure 3H) 
now showed significantly lower values in bigenic mice respective 
to controls. The number of entrances was equivalent in both 
groups in both social and non-social sides (RM-ANOVA, S-NS 
preference F(1,21)  =  2.76, p  =  0.11; genotype F(1,21)  =  0.21, 
p  =  0.64; interaction F(1,21)  =  0.02, p  =  0.88; Figure 3I), as 
was the interaction with the novel object (non-social control 
vs. bigenic comparison in Figures 3F,H) and the total traveled 
distance (16.57  ±  1.64 vs. 11.75  ±  1.74  m for control and 
bigenic mice, respectively; t(21)  =  1.967, p  =  0.063, Student’s 
t test). These results show that TDP-43-WT mice very rapidly 
develop alterations in social behavior, and these cannot 
be ameliorated by short-term suppression of transgene expression. 
Moreover, they support the idea that diverse behavioral domains 
present differential susceptibility to hTDP-43 overexpression 
and subsequent renormalization of TDP-43 levels.
Preserved Motor Behavior in TDP-43-WT 
Mice After Short-Term Transgene 
Overexpression and Upon Dox Treatment
Although TDP-43 proteinopathies include the FTD/ALS spectrum 
of disorders, only a subset of FTD cases present with motor 
abnormalities. In case of tTA/WT12 mice, we  described a 
progressive motor phenotype that slowly develops with increased 
time of hTDP-43 expression (Alfieri et al., 2016). In this mouse 
model, motor deficits are virtually absent at 1  month post-
induction but gradually emerge and are clearly present after 
12  months of transgene expression.
We assessed general motor function and exploratory activity 
in the 1  month (sup) group using the open field test 
(Figures  4A–D). In agreement with the data from 1  month 
induced mice (Alfieri et  al., 2016), bigenic tTA/WT12 mice 
that underwent the suppression protocol traveled the same 
distance as control animals (t(24)  =  0.6150, p  =  0.5444; 
Figures  4A,B). A more detailed analysis of this parameter, 
dividing the session in 5  min time bins, indicated that there 
was no averaging effect and both groups performed similarly 
in each of the time segments (Figure 4C). Moreover, relative 
center distance in this task was also indistinguishable from 
controls (t(24) = 0.7907, p = 0.4369; Figure 4D). Other parameters 
showed no differences (Student’s t test) between bigenic and 
control groups, including average speed (4.07  ±  0.33 vs. 
3.83 ± 0.21 cm/s for control and TDP-43-WT12 mice, respectively; 
t(24)  =  0.6294, p  =  0.5351), maximum speed (60.2  ±  8.9 vs. 
54.7 ± 4.2 cm/s for control and TDP-43-WT12 mice, respectively; 
t(24)  =  0.5888, p  =  0.5615), and percentage time in center 
(18.83 ± 1.67 vs. 16.81 ± 1.68% for control and TDP-43-WT12 
mice, respectively; t(24)  =  0.8465, p  =  0.4057).
Next, we  evaluated motor coordination and balance in 
TDP-43-WT animals using the accelerated rotarod test. Both 
bigenic and control mice behaved similarly in the 1  month 
(sup) paradigm (repeated-measures ANOVA, F(1,24)  =  0.9200, 
p  =  0.3470 for group; F(3,72)  =  44.09, p  <  0.0001 for trial; 
F(3,72) = 2.342, p = 0.0804 for interaction; Figure 4E). We also 
performed an analysis of limb clasping reflex phenotype. 
Both control and bigenic animals extended their limbs normally 
when being suspended by their tails, after 0.5  month of 
induction and subsequently after transgene suppression 
(Figure 4F). In addition, TDP-43-WT mice displayed 
indistinguishable latencies to fall in a hang wire test in the 
0.5  month induction and 1  month (sup) groups, indicating 
intact grip strength (Figure 4G).
These data indicate that: (1) motor abnormalities are not 
present after 0.5  month of transgene expression, consistent 
with our results after 1  month of hTDP-43 overexpression 
(Alfieri et  al., 2016) and (2) the suppression protocol had no 
unspecific effects on motor behavior, since locomotor/exploratory 
behavior, motor coordination, limb clasping, and grip strength 
were indistinguishable from controls.
In summary, we  present evidence that defines the early 
time course of behavioral impairments and establish the 
susceptibility of different behavioral domains to transgene 
suppression in tTA/WT12 mice (Figure 5).
FIGURE 5 | Summary of the behavioral phenotypes observed in tTA/WT12 mice after 0.5 or 1 month (from Alfieri et al., 2016) of hTDP-43 expression and in the 
1 month (sup) group. NS: non-significant differences respective to control mice.
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DISCUSSION
Animal models are invaluable tools to understand the pathological 
basis of neurodegenerative diseases such as FTD and ALS. In 
this study, we explored the behavioral consequences of suppressing 
hTDP-43 expression in our inducible tTA/WT12 mice.
The identification of disease-related molecules, the discovery 
of pathogenic pathways, and the targeting of pathogenic proteins 
are all critical steps to establish therapeutic strategies for 
incurable diseases, including neurodegenerative conditions. A 
major breakthrough was the discovery of TDP-43 as a pathological 
hallmark of ALS and FTD (Arai et  al., 2006; Neumann et  al., 
2006). Mutations in more than 25 genes have been shown to 
cause ALS and FTD, and it is noteworthy that most of these 
mutant proteins participate in two intracellular machineries: 
the RNA and protein quality control systems (Ito et  al., 2017).
TDP-43 belongs to a large family of RNA-binding proteins 
(RBPs) that have been shown to have multiple links with 
disease pathogenesis. Of specific relevance for neurodegenerative 
diseases, a prominent theory in the field states that neurons 
are particularly vulnerable to disruption of RBP dosage and 
dynamics (Conlon and Manley, 2017; Cookson, 2017). In 
particular, recent progress investigating the genetics of the 
FTD/ALS disease spectrum has shown that at least seven 
RBPs have been identified with disease-related mutations. 
These include TDP-43, FUS, the heterogeneous nuclear 
ribonucleoproteins (hnRNPs) hnRNPA1 and hnRNPA2B1, 
T  cell intracytoplasmic antigen (TIA1), TATA box-binding 
protein-associated factor 15 (TAF15), and Ewing sarcoma 
breakpoint region 1 (EWSR1) (reviewed in Ito et  al., 2017). 
This avalanche of information resulted in the development 
and characterization of multiple animal models of FTD/ALS 
based on the altered expression of these proteins (Lutz, 2018). 
These include TDP-43 models in both invertebrate (C. elegans, 
Drosophila) and vertebrate (mouse, rat) organisms (reviewed 
in Picher-Martel et  al., 2016). In addition to traditional 
transgenic and knockout technology, approaches such as 
application of CRISPR/Cas9 and viral transgenesis provide 
exciting alternative avenues to explore.
Inducible animal models based on the tet-tTA system have 
been used to assess the neuropathological and behavioral impact 
of expression of different neurodegeneration-associated proteins, 
including TDP-43, tau, APP, α-synuclein, SCA1, SCA3, and 
huntingtin (Yamamoto et  al., 2000; Zu et  al., 2004; Jankowsky 
et  al., 2005; Nuber et  al., 2008; Boy et  al., 2009; Sydow et  al., 
2011; Walker et al., 2015). However, only a few studies provided 
evidence for selective behavioral vulnerability to transgene 
suppression in neurodegenerative disease models.
Transgenic mice expressing TDP-43 carrying a pathogenic 
A315T mutation in CNS neurons display early motor and anxiety-
like phenotypes that are reversible on Dox treatment, while 
memory impairments persist after transgene suppression (Ke 
et  al., 2015). Our previous work in a mouse model expressing 
a cytoplasmic form of TDP-43 (TDP-43-∆NLS) demonstrated a 
differential response to transgene suppression, reversing the early 
motor and cognitive defects but having no effect of the sociability 
abnormalities developed by these mice (Alfieri et  al., 2014). 
In light of these recent examples, the evaluation of differential 
behavioral susceptibility to TDP-43-related dysregulation arises 
as a relevant parameter for understanding the progression of 
neurodegenerative disease manifestations, particularly in 
TDP-43 proteinopathies.
Our results show that cognitive performance, as evaluated 
in the Y-maze test, remains unaltered after 2 weeks of wild-
type hTDP-43 expression (0.5 month group). By contrast, 
we previously reported that expression of TDP-43-∆NLS using 
the same promoter system and induction protocol leads to 
a clearcut decrease in Y-maze alternation, reaching levels 
indistinguishable from chance and thus indicating severe 
deficits in spatial working memory (Alfieri et  al., 2014). 
While those animals recover their cognitive capacity when 
suppressed in the 1  month (sup) group, we  interpret the 
normal levels of tTA/WT12 mice Y-maze performance in 
1  month (sup) mice as evidence that we  are preventing the 
development of the working memory phenotype described 
in hTDP-43-WT mice with continuous expression for 1 month 
(Alfieri et  al., 2016). However, we  want to stress here that 
we  are not comparing the degree of cognitive dysfunction 
between the different expression time points (0.5 and 1 months) 
and the 1  month (sup) groups, but qualitatively assessing if 
a phenotype is present. The different onset time for cognitive 
deficits in our two inducible models highlights the fact that 
TDP-43-WT mice have a milder behavioral phenotype than 
TDP-43-∆NLS. This is also substantiated by the analysis of 
social and motor behavior.
In terms of social phenotype, our conditional hTDP-43-WT 
animal model recapitulates deficits that constitute a core feature 
of the clinical FTD/ALS spectrum, particularly in several 
subtypes of FTD (Shinagawa et  al., 2006; Sado et  al., 2009; 
Christidi et  al., 2018). Decreased sociability is a recurrent 
feature of FTD patients, and the three-chamber social interaction 
test used here demonstrates that TDP-43-WT mice develop 
social deficits very rapidly, after only 2  weeks of transgene 
expression (0.5 month group). Contrary to what happened 
with cognitive performance, sociability cannot be  rescued or 
preserved in these mice after short-term transgene suppression. 
Interestingly, TDP-43-∆NLS showed the same dynamics of 
social deficits, although the abnormalities were more profound 
in those mice (Alfieri et  al., 2014). Altogether, these data 
indicate that the neuronal circuits underlying these two different 
behavioral domains are differentially affected in TDP-43-WT 
mice, which, when considered in the context of a similar result 
from TDP-43-∆NLS animals, suggest an exquisite vulnerability 
for TDP-43-elicited changes in social function.
Although motor abnormalities develop after at least 6 months 
of transgene expression in TDP-43-WT mice (Alfieri et  al., 
2016), we sought to establish that (1) motor deficits at 0.5 month 
of expression cannot explain the phenotypes in other behavioral 
domains evaluated (in addition to the internal controls within 
each test) and (2) re-introduction of Dox treatment did not 
alter motor performance, eliminating thus the possibility that 
the treatment necessary for transgene suppression could 
be  interfering in the proper assessment or interpretation 
of behavioral tests performed in the 1  month (sup) group. 
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This is an important point, since it has been reported that 
Dox treatment may have non-specific effects on certain behaviors, 
although the strain more resistant to these effects was C57BL/6J 
(Han et  al., 2012) and our TDP-43 inducible mouse models 
are backcrossed to C57BL/6J for >10 generations to homogenize 
genetic background.
A limitation (but also an advantage) of this model is that, 
due to the pattern of expression provided by the driver transgenic 
line (CamKII promoter), which results in forebrain-enriched 
neuronal hTDP-43-WT expression, part of the phenotype can 
be  restricted due to sparing of other regions (including spinal 
cord). However, there are other rodent models available with 
pan-neuronal TDP-43 expression (summarized in Picher-Martel 
et  al., 2016) and comparison of our results with those can 
provide important clues on regional involvement.
Our results showing differential behavioral susceptibility to 
transgene suppression in our inducible TDP-43-WT mice 
stimulate further questions regarding the underlying mechanisms 
behind these differences. Additional research is warranted, 
exploring selective regional neurodegeneration and 
neuroinflammation, as well as the potential role of non-neuronal 
cells (i.e., astrocytes and microglia) as contributors to 
this phenotype.
In summary, we show here that not only TDP-43-WT mice 
recapitulate several core behavioral features of FTD/ALS 
spectrum of human pathology, but also these behavioral 
domains display a different time course of onset and sensitivity 
to transgene suppression. This information is particularly 
relevant to understand both the time windows of efficacy for 
potential treatments and the selectivity/sensitivity to TDP-43 
dysregulation of the neural circuits underlying the clinical 
phenotypes displayed by FTD/ALS patients. We  also consider 
that our inducible model is especially relevant to explore the 
etiology of TDP-43-related FTD, due to the predominant 
social/cognitive phenotype with early sparing of motor symptoms 
(which only appear after long-term expression of the transgene; 
Alfieri et  al., 2016). The information provided from this and 
future studies using this animal model might shed light into 
the pathological mechanisms of TDP-43 proteinopathies and 
help devise potential therapeutic avenues for these 
devastating conditions.
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